(NOTE: A public offering: Our ordinary shares are listed on Euronext Paris under the symbol “IVA.” On July 8, 2020, the closing price of our ordinary shares on Euronext Paris was €14.28 per ordinary share, equivalent to a price of $16.17 per ADS, assuming an exchange rate of €0.8833 per U.S. dollar, based on the exchange rate on July 8, 2020. .)

We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, and other diseases with significant unmet medical need. We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.